Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

–         Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – –         Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S. – –         Data presented today at ACC 2024 and published in The New England Journal of Medicine – –         Ionis to host webcast on Mond ...